Publications

• Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
  Blood Adv Volume: 7 Page(s): 4528 - 4538
  08/22/2023 Authors: Major A; Yu J; Shukla N; Che Y; Karrison TG; Treitman R; Kamdar MK; Haverkos BM; Godfrey J; Babcook MA
• A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
  Blood Adv Volume: 7 Page(s): 2983 - 2993
  07/11/2023 Authors: Sawalha Y; Goyal S; Switchenko JM; Romancik JT; Kamdar M; Greenwell IB; Hess BT; Isaac KM; Portell CA; Mejia Garcia A
• Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
  Blood Adv Volume: 7 Page(s): 2657 - 2669
  06/27/2023 Authors: Zurko J; Nizamuddin I; Epperla N; David K; Cohen JB; Moyo TK; Ollila T; Hess B; Roy I; Ferdman R
• Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
  Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
  12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA